Tuszynski et al. initiated a clinical trial of NGF gene therapy in patients with early-stage AD and confirmed that NGF improves the function of degenerated neurons in the brain tissue of AD patients without obvious side effects [68,69]. Here, NGF is linked to Alzheimer disease.